Edgewise Therapeutics (EWTX) Cash & Equivalents (2020 - 2026)

Edgewise Therapeutics (EWTX) has 7 years of Cash & Equivalents data on file, last reported at $33.2 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 33.47% year-over-year to $33.2 million; the trailing twelve-month figure through Mar 2026 stood at $33.2 million (down 33.47% YoY), and the FY2025 full-year result was $61.1 million, up 46.76% from the prior year.
• Cash & Equivalents fell to $33.2 million in Q1 2026, from $61.1 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $563.3 million in Q3 2025 to a low of $22.0 million in Q4 2022.
• A 5-year average of $145.6 million and a median of $48.2 million in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents soared 1394.37% in 2024 and plunged 90.63% in 2025, its largest moves.
• Tracing EWTX's Cash & Equivalents over 5 years: stood at $22.0 million in 2022, then jumped by 291.47% to $86.1 million in 2023, then tumbled by 51.61% to $41.7 million in 2024, then surged by 46.76% to $61.1 million in 2025, then slumped by 45.69% to $33.2 million in 2026.
• Business Quant data shows EWTX's Cash & Equivalents at $33.2 million in Q1 2026, $61.1 million in Q4 2025, and $563.3 million in Q3 2025.